Levebon

Levetiracetam, the active ingredient in Levebon, is an anticonvulsant presented as an oral tablet for oral use. It treats partial seizures, generalized tonic‑clonic seizures and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and severity. GNH USA supplies Levebon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is employed to manage epileptic seizure disorders across several seizure types.

Partial seizures: reduces the frequency of focal onset seizures and improves seizure control. Generalized tonic‑clonic seizures: helps prevent convulsive episodes and lowers seizure recurrence. Myoclonic seizures: decreases the occurrence of sudden muscle jerks and improves daily functioning.

Levetiracetam may cause a range of adverse reactions. Monitoring and reporting are important for patient safety.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Suicidal thoughts or severe depression - Blood dyscrasias including neutropenia or thrombocytopenia - Hepatic failure or significant liver enzyme elevation

Before initiating therapy, clinicians should consider several precautionary measures.

Renal impairment: adjust dose based on renal function and monitor serum levels. Hepatic impairment: evaluate liver function and consider dose modification. Pregnancy: risk category unknown; discuss potential benefits and risks with the patient. Breastfeeding: unknown safety; weigh maternal benefits against possible infant exposure. Concomitant CNS depressants: may increase sedation and should be used with caution. Store at room temperature: keep in the original packaging, protect from moisture and excessive heat.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam concentrations. - Phenytoin: may reduce levetiracetam plasma levels. - Phenobarbital: can decrease levetiracetam exposure through hepatic induction. - Valproic acid: may increase levetiracetam levels and risk of adverse effects.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may enhance sedation. - Sedative antihistamines: can increase drowsiness. - Other antiepileptics: may have additive seizure‑control effects requiring dose adjustments.